ReviewInternational journal of molecular sciences2013
The present and future of prostate cancer urine biomarkers.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles.Journal of extracellular vesicles · 2021Guideline
- Evaluating Differential Metabolic Profiles by Prostate Cancer Risk Among Prostate Cancer Patients.Metabolites · 2025Article
- High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort.Biomarker research · 2025Article
- CAP superfamily proteins in human: a new target for cancer therapy.Medical oncology (Northwood, London, England) · 2024Review
- Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications.International journal of molecular sciences · 2024Review
- Emerging Multifunctional Carbon-Nanomaterial-Based Biosensors for Cancer Diagnosis.Small science · 2024Article
- Potential Diagnostic Biomarker Detection for Prostate Cancer Using Untargeted and Targeted Metabolomic Profiling.Current issues in molecular biology · 2023Article
- Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation.Diagnostics (Basel, Switzerland) · 2023Article
- Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis.Journal of cancer research and clinical oncology · 2023Review
- Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis.Current oncology (Toronto, Ont.) · 2023Review
- Article
- A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs.Bioengineering & translational medicine · 2023Article
- Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.British journal of cancer · 2022Review
- On an Affordable Approach towards the Diagnosis and Care for Prostate Cancer Patients Using Urine, FTIR and Prediction Machines.Diagnostics (Basel, Switzerland) · 2022Article
- Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study.Turkish journal of medical sciences · 2022Article
- Delineating the role of extracellular vesicles in cancer metastasis: A comprehensive review.Frontiers in immunology · 2022Review
- Fibromodulin Gene Variants (Disease markers · 2022Article
- Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.International journal of molecular sciences · 2021Review
- Article
- JPX and LINC00641 ncRNAs expression in prostate tissue: a case-control study.Research in pharmaceutical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput "omic" techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.